Single arm phase 2 study | Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for hematopoietic stem cell transplantation.
19 Jul, 2022 | 13:00h | UTCLisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: Second-Line CAR-T Impresses in Transplant-Ineligible Large B-Cell Lymphoma – MedPage Today (free registration required)
Related:
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
Online first: #Lisocabtagene maraleucel as second-line therapy in adults with R/R large B-cell #lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study https://t.co/NwkfPmVHu0 #lymsm pic.twitter.com/jHj5rFadV2
— The Lancet Oncology (@TheLancetOncol) July 13, 2022